Movement Alert｜Kodiak Sciences Inc. Falls 5.6% in Regular Trading, Earlier Insider Buying Tailwind Loses Momentum

Market Focus10-14

On October 14, Kodiak Sciences Inc. fell 5.6% in Regular Trading, trading at $86.2128 per share, with turnover of $28.4683 million.

The most relevant recent catalyst is a fading follow-through from late-September insider buying, after a prior rally driven by positive Phase 3 eye-drug data and a large director-linked share purchase.

Felix Baker, a director, bought about $157 million of shares through Baker Bros. Advisors at roughly $80.85 per share on September 29, described as his largest purchase to date, lifting the affiliated funds' stake to about 35%. Earlier, the company said two eye-drug candidates, Zenkuda and tabirafusp-ted, met primary endpoints in a Phase 3 wet AMD study, which had helped push the stock sharply higher. The current pullback suggests the marginal boost from those positives has weakened.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment